Company Interview / Recce strengthens its patent armour

Key points:

New Vietnam patent extends protection of Recce’s lead anti-infective compounds to 2041Late-stage phase three trial in Indonesia targeting diabetic foot ulcer infections, with ASEAN-wide ambitionsBroad portfolio of over 40 patents and three synthetic broad-spectrum candidates focused on bacterial infections

James Graham from Recce Pharmaceuticals outlines a major expansion of the company’s intellectual property footprint, with a newly granted patent in Vietnam extending protection of its lead anti-infective compounds to 2041. Graham states this is the eighth granted patent in one patent family and forms part of a broader portfolio of more than 40 patents across markets including Australia, China, Japan, Canada and Brazil. He views Vietnam as strategically important given high antibiotic resistance and rising rates of diabetes-related infections.

Graham highlights a late-stage phase three trial in Indonesia targeting diabetic foot ulcer infections, which he expects could become the first standard of care in that indication by the end of the calendar year. He argues that positive data there could support approvals across ASEAN, including Vietnam, where he sees a major unmet medical need in diabetic foot, burn, skin and potentially lung infections.

According to Graham, Recce has three synthetic broad-spectrum drug candidates focused on bacterial infections, with some viral applications in modified forms. He notes support from three US Department of Defense programmes and points to strengthened finances following a $4 million share placement and sizeable, government-guaranteed R&D tax rebates.